Background: The majority of adults diagnosed with obstructive sleep apnoea (OSA) are overweight or obese. Continuous positive airway pressure (CPAP) is the most common effective therapy for OSA. However, adherence declines over time with only 50% of patients prescribed CPAP continuing to use it long term. Furthermore, a recent prospective analysis indicated that those more adherent with CPAP therapy have enhanced weight gain trajectories which in turn may negatively impact their OSA. Aim: The Sleeping Well Trial aims to establish whether the timing of starting a lifestyle weight loss intervention impacts on weight trajectory in those with moderate-severe OSA treated at home with CPAP, while testing the potential for smart phone technology to improve adherence with lifestyle interventions. Methods: A stepped wedge design with randomisation of individuals from 1 to 6 months post-enrolment, with 5 months of additional prospective follow up after completion of the stepped wedge. This design will investigate the effect of the 6-month lifestyle intervention on people undergoing CPAP on body weight, body composition and health-related quality of life. Discussion: This trial tests whether the timing of supporting the patient through a weight loss intervention is important in obtaining the maximum benefit of a lifestyle change and CPAP usage, and identify how best to support patients through this critical period. Trial Registration: The protocol (v1) is registered prospectively with the International Clinical Trials Registry (CTR) ACTRN12616000203459 (public access). Any amendments to protocol will be documented via the CTR. Recruitment commenced in March 2016 with data collection scheduled to finish by May 2018.
Introduction
Obesity and sleep disordered breathing are highly correlated. 1 The increased prevalence of obesity and, subsequently, obstructive sleep apnoea (OSA) has led to increased demand for treatment of this sleep disorder. Currently, moderate-severe OSA is estimated to affect 10% of men and 3% of women aged 30-49 years which increases to 17% of men and 9% of women aged 50-70 years. 2 Although not all with OSA are overweight, significant proportion are (70%) and severe OSA is an independent risk factor for cardiovascular disease, insulin resistance, type 2 diabetes and stroke. 1 Many patients who lose weight experience an improvement in their OSA. 3 However, the situation is not simple and the relationship is not unidirectional. A systematic review to explore the relationships between OSA and body weight concluded that there was strong evidence that obesity contributes to the pathogenesis of OSA. 4 However, the review also reported that the presence of OSA can reinforce the obese state via alterations to energy metabolism, appetite and satiety (via neural control feedback mechanisms), thereby making it harder for those with OSA to manage their weight and maintain weight loss.
Continuous positive airway pressure (CPAP) is accepted as 'best practice' treatment for moderate-severe OSA. In a report prepared for the Australasian Sleep Association, 5 CPAP treatment was found to be both clinically and cost effective, with an incremental cost effectiveness ratio of $5K per quality adjusted life year. However, the report also highlighted that patient adherence with CPAP therapy is suboptimal with less than 50% using this therapy long term. Adherence with treatment appears to decline quickly despite reduction in daytime sleepiness. 6 Ongoing support and the patient's initial experiences with CPAP have been shown to be predictors of success. 7 Importantly, CPAP may have a negative impact on a subject's weight. A meta-analysis involving 25 randomised trials on patients with OSA found that commencing CPAP treatment resulted in a significant increase in weight and body mass index (BMI). 8 Despite this, patients on CPAP do have the ability to lose weight, further leading to an improvement in cardiovascular risk profile. Chirinos et al. 9 reported that weight loss plus CPAP was more effective than CPAP alone at improving insulin sensitivity, blood pressure and serum triglycerides. In this study, there was an impressive 11 kg difference in weight between groups, with those randomised to receiving support to lose weight achieving sufficient weight loss to be clinically important in reducing their cardiovascular risk (5-10% body weight).
A comprehensive review of the literature concluded that weight loss via diet and/or exercise interventions are effective in the treatment of OSA. 3 In the included meta-analysis, a mean weight loss of 13.76 kg (95% CI 8.32, 19.21) and a mean reduction in Apnoea Hypopnea Index (AHI) of 16.09 (95% CI 6.54, 25.64) was observed. What was also apparent from this meta-analysis and from other studies 10 is that loss of body weight is important in enabling remission of sleep symptoms (daytime sleepiness, morning headaches) independent of any improvement in OSA severity and that diet approaches are the most effective. Most of these studies had follow-up periods extending out to 1 or 2 years. To date, only one study has had a long term (60 month) follow up. 7 This study was observational and designed to determine if weight loss from a 1-year randomised controlled trial could be maintained and prevent progression of OSA over the long term. The authors reported an 80% improvement in the progression of OSA in those who maintained weight loss. However, a key limitation of this work is that it only recruited those with mild OSA so it remains contentious if lifestyle interventions can objectively cure those with moderate or severe OSA. 7 Recently, fasting regimes which reduce energy intake on specific days per week and without restriction on remaining days have gained popularity, are simple to follow and have proven just as effective for weight reduction, at least in the short term, than a consistent reduction in daily energy intake. 11 Previously, we have reported success in younger adults, with a modified 5:2 fasting regimen which incorporates a 2-day 'fasting' per week and 5 days of healthy eating, which will be used in this study. 12 Changes in diet (energy in) and activity (energy out) are the cornerstones of any lifestyle intervention 13 but require sustained behaviour changes to counteract the physiological compensatory processes which favour weight re-gain.
14 Those newly diagnosed with OSA have to contend with the use of a CPAP machine, which requires shifts in behaviour both for the patient and potentially any bed-partner. Behaviour change theory clearly indicates that asking people to undertake multiple simultaneous changes is fraught with difficulty. 15 We have highlighted the importance of actively addressing obesity alongside CPAP, but simultaneously commencing CPAP and making multiple complex changes to their diet and exercise regime concurrently (i.e. lose weight plus start CPAP) increases the risk of failure. 16 Adherence to CPAP itself declines up to 83% over the first 3 months of treatment in some studies, indicating that more support is required on initiation to establish this new behaviour, particularly before moving forward with additional lifestyle changes. 17 Therefore, current practice may present potential barriers for patients; multiple concurrent lifestyle changes are expected (CPAP initiation plus weight loss) but with little support. Strategies that separate the initiation of these two therapeutic interventions, such as in using step-wedged intervention designs, where commencement of the intervention of interest are staggered, 18 enable each participant to be exposed to the interventions and does not require an untreated control group.
Providing long-term support to patients is challenging in a health service model designed to prioritise acute care. Following initial education, patients may be left to implement changes on their own. Motivation, improving self-efficacy and social support are key adjuncts to successful long-term behaviour change and any intervention that can incorporate behaviour modification in addition to pure 'education' is likely to have a longer term impact. 13 Accessibility to lifestyle interventions has moved into a new age with the wide spread uptake of smart phone technology. New technology and smart phones in particular can be used to remind and enable self-monitoring of progress, from which participants gain motivation. 19 Sleeping Well Trial uses an application called MyPace (White October, Oxford UK)-designed by psychologists grounded in behaviour change theory and tested in the context of weight loss. This App provides tailored motivational text messages, reminder messages to prompt desired behaviours, a weight tracker to show progress towards agreed goals and additional support to the user as they can message their dietitian in between face-to-face appointments. 20 Research on the Sleep Well Trial protocol integration of technology into health care suggests that the right application may be positively accepted by both consumers and practioners. 21 Furthermore, health-care systems in Europe, Australia and the United States are currently actively encouraging and investing in technological innovations to support available routine care. 22 Time spent in face-to-face contact between individual patients and a health-care professional represents a significant use of resources. Any additional contact time needs to have demonstrable benefits and outcomes.
Thus, the aims of the trial are as follows: Primary aim 1: Investigate the effectiveness of a 6-month lifestyle intervention for reducing body weight in overweight subjects with moderate-severe OSA commencing CPAP.
Primary aim 2: Determine whether timing of commencement of a lifestyle intervention affects the change in weight and trajectory of weight experienced 12 months following CPAP commencement.
Secondary aim 1: Examine whether people who commence CPAP gain body weight.
Secondary aim 2: Examine the potential for smart phone technology to improve adherence with interventions, both lifestyle (diet and physical activity, PA) and with selfadministered CPAP and extend the reach and impact of face-to-face advice which is the traditional model of care in hospitals.
Methods
Trial design and participants: We employ a stepped wedge design with randomisation of individuals with 5 months of additional follow-up following completion of the stepped wedge (7 months, Figure 1 ). The stepped wedge design 18 will be used to investigate the effect of the lifestyle intervention on OSA patients receiving CPAP therapy on body weight, body composition and health-related quality of life. We chose not to use sham CPAP as a control as there are ethical issues in not providing CPAP treatment to this patient group. Crucially, this design enables us to test whether the timing of the intervention delivery impacts on both the absolute change and rate of change in weight by the 12-month post-recruitment assessment.
Ethics approval has been granted from Monash Health and Monash University Human Research Ethics Committee (CF1) HREC/15/MonH/93 Ref 15357A. Dissemination will be via peer-reviewed publications and international presentations. This manuscript was written in accordance with the SPIRIT and CONSORT guidelines.
Recruitment:
The recruitment phase for this trial commenced in March 2016 and was completed in May 2017. Participants were recruited from two separate Academic sleep centres (Monash Health and Eastern Health) in Melbourne, Australia, which both follow best practice OSA treatment guidelines. 23 Eligible participants were identified and referred by their treating sleep physicians, or self-referred via approved advertising posters displayed in clinic.
Inclusion criteria: Patients with moderate-severe OSA (defined by an AHI ≥ 20/hour determined from overnight polysomnography (PSG) according to standard American Academy of Sleep Medicine criteria) 24 and starting CPAP therapy were included. Additional inclusion criteria: patients between 19 and 68 years, self-reported sedentary lifestyle (as per trial registration, engaged in PA less than 2 days per week and a duration of less than 45 minutes per session).
Exclusion criteria: Those of Caucasian descent who have a BMI within the healthy range (BMI < 24.9); of Indian and Chinese descent with a BMI <23; persons with a BMI >43. Those with an urgent need for CPAP (e.g. commercial or drowsy drivers defined by Epworth Sleepiness Score > 16), 25 those who were unable to provide informed consent in English, were already on a diet/exercise program or diagnosed with concomitant obesity hypoventilation syndrome were excluded after their PSG study. Additional exclusion criteria: pregnant women, an inability to exercise, receiving VPAP/BPAP, previous treatment for OSA, previous bariatric surgery or persons already on a diet, and those suffering from angina pectoris/atrial fibrillation.
Procedure: Patients identified by their treating sleep physician and meeting eligibility criteria provided verbal consent to be further contacted by the trial team by telephone. Selfreferring participants were encouraged to phone or email researchers directly (eligibility subsequently confirmed by treating sleep physician). Individuals expressing interest in participating in the trial were then invited to attend a morning screening session after a fast of 10-12 hours the evening prior where inclusion/exclusion criteria were confirmed. Upon written consent, participants were enrolled into the trial, allocated to a treatment group and informed of their wait list period (CB, KD and LG). Group 1 began the lifestyle intervention 1 month after starting CPAP therapy; Group 2 after 2 months, Group 3 after 3 months and so forth, up to a maximum 6 month waiting period. Participants have been asked to continue with their normal lifestyle until their intervention period commences. Once the lifestyle intervention has commenced, it continues for 6 months. This design enables us to randomise each individual participant into groups and then enrol each group to the lifestyle intervention at different time points. Treatment allocation was stored in opaque envelopes and remained unknown until revealed to the researcher on the day each participant was allocated to a group. Randomisation took place using allocation concealment by the trial statistician (TH). Masking participants to group allocation was not possible due to the necessity to participate in the diet intervention. Participants were asked not to reveal their group allocation to their treating CPAP technicians or sleep physician who were blinded to group allocation. Visits for data collection at the university used a staggered by appointment time, thus minimising any likelihood of participants meeting each other. Following randomisation (LG, CB and KD), participants' weight was assessed using a calibrated digital scale (Seca, Hamburg, Germany). Subsequently, their blood pressure, height, waist and neck circumference was measured using standard laboratory operation procedures. A qualified phlebotomist then obtained a 17 mL blood sample from each participant. Blood samples were immediately spun via centrifuge and stored in Eppendorf tubes in a −80 C biohazard freezer in the research laboratory at Monash University. After blood collection, a light breakfast was provided to participants while they complete a series of validated questionnaires (see Diet, eating behaviour, sleep, activity and psychosocial measures). An appointment for the participant to visit the CPAP provider within 1 week of the screening session was organised by the researchers at the end of the session.
Patients underwent mask fitting and education regarding OSA and were provided with a CPAP machine by staff at Air Liquide Healthcare, and access these staff for ongoing support at no cost. Patients are initially commenced on Autotitrating CPAP using a Resmed S9 CPAP machine. After 1 week of treatment, patients are switched to fixed pressure CPAP based on the 95th centile pressure determined during the autotitration week. Routine equipment troubleshooting is provided by Air Liquide staff at the CPAP centres. The participants' treating sleep physician coordinates all CPAP care and is responsible for any decisions regarding treatment changes. Participants are required to use their CPAP devices regularly for the 12-month period (beginning from consent date). Upon completion, participants will be encouraged to continue standard treatment in collaboration with their treating sleep physician.
Monitoring: After enrolling into the trial, all participants are contacted monthly to determine a time for a 10-minute visit at home or at clinic to be weighed. Participants are also asked to provide their CPAP device at the end of the 12-month period so data on usage can be extracted from its built-in memory. These data will provide objective measures of adherence with CPAP therapy and their weight trajectory over time. Any participant who withdraws from the trial will be encouraged to continue standard treatment with their initial referring sleep physician and their weight will be collected from their medical record.
Lifestyle intervention: Participants are prescribed a modified fasting diet regime (5:2) with PA recommendations of 3 x 30 minutes per week of light/moderate PA (e.g. increase step count, begin resistance training, low-impact swimming, etc.) for the initial 3 months, followed by a 3-month maintenance phase ( Table 1 ). The dietary regimen consists of 5 days of restricted daily energy intake of 6300-7500 kJ per day and 2 days of very low energy intake between 2200 and 2760 kJ per day. On very low energy intake days, participants are provided with low energy milk shakes, multivitamins with fish oil, fibre and iron (women only) supplements contained in labelled sachets. A single trial dietitian (KR) supports each subject by a face-to-face monthly visit (initial 60 minutes, follow-up 30 minutes) using behaviour change and motivational interviewing techniques augmented in between appointments via communication via the MyPace App. The App enables out-of-clinic communication between the dietitian and the participant, including regular reminders, troubleshooting, motivational messages/encouragement and progress reports. The six face to face consultations with an Accredited Practicing Dietitian are designed to enable the participant to set their individual goals in relation to change in diet choices and activity, which develops the individuals' capability to manage their food and activity in the context of their own physical, social and psychological environment. These goals are then programmed into the App which generates automated but predetermined motivational and supportive messages to the participant. Adherence can be assessed via monitoring the closed communication with the dietitian which occurs via the MyPace App. Participant satisfaction with the intervention is requested at the end of the trial and collected via an anonymous semistructured questionnaire. Analysis of these questionnaires enables Sleep Well Trial protocol researchers to gain participant insight into aspects of the intervention content, delivery style and structure.
Outcomes: The trial is powered on the primary outcome of weight change over time. Weight (kg) is measured using standard techniques at each centre on diagnosis, at the start of CPAP and then monthly at follow-up visits at either the CPAP centres, routine hospital visits or dietitian visits. Digital weighing scales (Seca) are provided at each site or centre to ensure patients are weighed on the same device each month and all staff trained in the standard operating procedure, with routine calibration throughout the duration of the trial. Home visits are available for those who are unable to attend any other options. MyPace application adherence is monitored via in-app message usage. Participants are also asked to rate the MyPace App's usefulness in an end-of-trial feedback form.
Other outcome measures: CPAP adherence is measured by regular machine downloads to document hours and days used. In addition, residual AHI on treatment is continually measured via participants' CPAP device, with a final reading taken at 12 months at both the CPAP centre (by CPAP technicians) and main research facility at Monash University (by the study coordinator). Body composition is measured using the reference technique of GE Lunar iDXA (GE Medical, Software Lunar DPX enCORE 2012 version 14.0, Madison, Wisconsin). Waist and neck circumferences are measured at the same time points as weight verification and blood pressure are monitored.
Blood samples are drawn at screening, baseline, at the end of the lifestyle intervention and at 12 months to measure cholesterol (HDL:LDL), triglycerides, glucose and insulin for monitoring of metabolic cardiovascular risk factors. To gain insight into the molecular mechanism underlying weight change in OSA patients undergoing CPAP, peripheral blood mononuclear cells are isolated from a blood sample at the beginning and end of the weight loss phase to analyse transcriptome modulation in a sub-set (~10) of participants. The transcriptome analysis will involve RNA sequencing, cluster analysis and pathway enrichment to determine overexpressed pathways in this population.
Diet, eating behaviour, sleep, activity and psychosocial measures: The following validated questionnaires are completed at screening, baseline, at the end of the lifestyle intervention and at 12 months with data collected from the participant via an iPad and directly uploaded to the trial database: Functional Outcomes of Sleep questionnaire (FOSQ), 26 Epworth Sleepiness Scale (ESS), 25 eating behaviour (TFEQ-R18), 27 Health-Related Quality of Life (EQ-5D), 28 self-reported activity (IPAQ-SF), 29 general health status (SF-36), 30 and history of depression (BDI) 31 and anxiety (HADS).
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Diet is measured using a standardised 24-hour recall by the trial dietitian at the beginning of the intervention period and after 6 months. Nutrient analysis of macro-and micronutrients will be performed using Foodworks 7 (Xyris Software Pty Ltd., Brisbane, Australia) and performed in duplicate by two independent researchers. Adherence to the dietary plan is monitored by counting unused milkshake and supplement sachets provided over the dietary intervention period and monitoring of the App usage and in-built messaging is used as an indicator of adoption of behaviours and engagement with the support and goal setting provided via the App. Activity is recorded using FitBit 'Flex' devices (FitBit, San Francisco, California) supplied to participants' at time of enrolment, these data being stored on participants' online accounts and accessible by researchers for the duration of the trial. Participants are requested not to change their account password from the one provided at time of set up for the duration of the trial.
Statistical analysis plan: Analyses will be undertaken using the 'intention-to-treat' approach, where all evaluable data is analysed in the treatment group according to which the participant was allocated. Statistical significance will be defined as α < 0.05. All tests conducted will be two-tailed.
We will use multilevel, mixed effects, generalised linear models to investigate primary aims 1 and 2. We will address primary aim 1 from the short-to medium-term perspective using data only from the stepped wedge portion of our design (analysis 1), and from the medium to long-term Review progress, record weight measurement, monitor adherence to fasting days, review goals from last appointment and discuss barriers/ enablers to achieving these 3
Review progress, record weight measurement, monitor adherence to fasting days, review goals from last appointment and discuss barriers/ enablers to achieving these, discuss strategy moving into maintenance phase and cessation of fast days take weight measurements 4
Review progress, record weight measurement, review goals from last appointment and discuss barriers/enablers to achieving these 5
Review progress, record weight measurement, review goals from last appointment and discuss barriers/enablers to achieving these, prepare participant to end relationship with dietitian after the next visit, start to think about discharge strategy 6
Review progress, record weight measurement, review goals from last appointment and discuss barriers/enablers to achieve these, provide follow-up options and ensure that a strategy for maintenance/further weight loss is in place perspective using combined data from the stepped wedge portion of our design and the prospective follow up (analysis 2). The dependent variable will be the rate of weight loss or gain relative to their previous assessment ((previous weight subtracted from present weight) divided by period of time between these assessments). Participant number will be treated as a random effect within the model to account for the dependency of observations within each participant. A categorical fixed effect coding for month since trial commencement will be included to account for maturation effects as per guidelines for analysis of stepped wedge trials. 33, 34 We will address primary aim 2 using analysis 2, but with the addition of an intervention-by-month of commencement interaction effect. Month of commencement will be entered into the model as a categorical variable. Primary aim 2 will additionally be investigated using an Analysis of Covariance style linear regression analysis approach (analysis 3). Here, only the final baseline assessment of weight treated as a raw score will be used as the dependent variable. Month of commencement of the intervention will be used as a categorical independent variable. The first weight measurement treated as a raw score will be used as a covariate. If this analysis reveals a linear, quadratic or other trend in the effect of month of commencement on the dependent variable, then an additional analysis will be undertaken (analysis 4) where the month of commencement independent variable is entered into the same model as a continuous variable with or without transformations as indicated. Average CPAP treatment adherence since the previous assessment will be used as a covariate in each of these analyses.
Secondary aim 1 will be assessed using only preintervention period data from the stepped wedge portion of this trial. These data will test secondary aim 1 using a pre-post intervention design which generates a quasiexperimental standard of evidence as potential maturation biases cannot be accounted for. Here, weight measurements taken at the baseline assessment (prior to CPAP commencement) will be compared to those taken after this following commencement of CPAP. This aim will be examined using a multilevel, mixed effects, generalised linear model (analysis 5). Trial participants will be treated as a random effect and the presence or absence of CPAP will be used as a fixed independent variable. The impact of CPAP will be further examined using a contaminationadjusted intention-to-treat analysis (analysis 6) 35 which will account for participants with poor CPAP adherence potentially contaminating the estimate of the impact of CPAP commencement on body weight. A further analysis will be conducted including a CPAP-by-time since CPAP commencement interaction effect into the same model as analysis 5 (analysis 7). This interaction effect will be examined for a linear, quadratic or other trend in the effect of month of commencement on the dependent variable. If a pattern is identified, an additional analysis will be undertaken (analysis 8) where the month since commencement of CPAP-independent variable is entered into the same model as analysis 5 but as a continuous variable with or without transformations as indicated.
The effect of average CPAP treatment adherence since the previous assessment will be used as a covariate multilevel, mixed effects, generalised linear model. The dependent variable will be the rate of weight loss or gain relative to their previous assessment.
Sample size calculation: The stepped wedge component of this design has six separate 'steps'. By recruiting seven participants for each of the six starting time points of the lifestyle intervention, we have 90% power to detect a standardised effect size of 0.40 for the rate of change in body weight outcome for analysis 1. This assumes a conservative Intraclass correlation coefficient of 0.10, two-tailed α = 0.05, and treats each individual participant as its own cluster (as this is the unit of randomisation). Collecting 10 participants per group to maintain trial power will provide coverage within the trial for a potential drop-out/missing data rate of over 30%.
Trial management and dissemination: The trial will continue to be conducted according to research governance principles set out by Monash Human Research Ethics Committee whom maintain the right to audit the trial at any stage. Participant data are collected, entered and stored according to standard confidentiality procedures on a secure server with password-only access and in locked filing cabinets during and following the trial period. All data will be cross-checked by an independent researcher throughout the trial and may only be accessed by the research team. Trial progress will continue to be monitored via monthly collaborative group meetings with the research team whom are ultimately responsible for any decisions regarding the fate of the trial. The trial findings will be presented at conferences and will be reported in peer-reviewed journals by the research team. Any dissemination of the research findings will be by group level data only to protect privacy and confidentiality rights.
Results
A total of 60 participants have been recruited into the trial (between 22 March 2016 and 11 May 2017). Recruitment was initially predicted to last 6 months, but took longer due to the BMI criteria excluding some potential participants (both higher and lower than inclusion criteria) and being confirmed as having 'mild' rather than 'moderate-severe' OSA after their overnight sleep study. Figure 2 details the recruitment process from both hospital sites. The majority of participants are male (n 44 (73%), with a mean (SD) age of 49.35 years (AE10.74)). The mean (SD) BMI is 34.26 (AE4.6) with a range of 25.7-43 and with moderate-severe OSA as defined by AHI (mean 46.85 (AE21.14)). Twelve (20%) participants reported being on antidepressants at the time of enrolment and 14 (23%) on medication for hypertension.
Discussion
As there is growing evidence that CPAP alone may at best support the obese state and at worse lead to increasing weight Sleep Well Trial protocol in a population vulnerable to weight gain, there is a strong rationale for adding a lifestyle-based weight loss intervention to the treatment of all overweight or obese OSA patients prescribed CPAP at home. It is also important to understand the impact of a lifestyle intervention on metabolic outcomes and psychosocial behaviours. This trial tests whether the timing of supporting the patient through a weight loss intervention is important in obtaining the maximum benefit of a lifestyle change and CPAP usage, and identify how best to support patients through this critical period.
It will extend our knowledge of the aetiology of weight trajectory in patients with moderate to severe OSA who are prescribed CPAP therapy, which is currently lacking. Importantly, the findings will extend our knowledge of treatment pathways that are applicable in practice settings, particularly whether the timing of weight management starts and how that impacts on outcomes. It also examines whether extending the impact and reach of lifestyle interventions with a comprehensive program, including the use of smart phone technology, improves adherence and therefore treatment effectiveness. Thus, the 'Sleeping Well Trial' has the potential to encourage a movement towards more personalised interventions to achieve maximal benefit and engagement based on delivery timing and method of communication between dietitian and patient.
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